Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cronos Group Inc (CRON) vs Entegris Inc (ENTG) Price & Performance

Cronos Group IncTrade
Entegris IncTrade

Price performance (Past 24H)

Key statistics

Cronos Group Inc vs Entegris Inc — how do they compare? Cronos Group Inc trades at $3.22 (market cap $1.18B), while Entegris Inc trades at $165 (market cap $24.78B). The key difference: Entegris Inc is far larger — about 21× Cronos Group Inc's market cap, and Entegris Inc pays a 0.25% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Entegris Inc for 41 Days on average.

CRONENTG
Market Cap
$1.18B$24.78B
Volume
968,0372,648,320
Sector
HealthTechnology
52-Week High
$3.55$184.00
52-Week Low
$2.30$68.80
Typical Hold Time
22 Days41 Days
Enterprise Value
$387.62M$27.99B
Dividend Yield
—0.25%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cronos Group Inc

CRON trades at $3.23, down 0.31% with a bearish technical signal. Recent earnings show volatility with Q2 2026 beating expectations ($0.09 vs $0.01) but Q4 2025 missing. Revenue grew from $118M (2024) to $147M (2025), though net income turned negative at -$9M. The company maintains strong liquidity with $827M cash and no debt, highlighted in recent investor day presentations.

Outlook is mixed: analyst consensus leans Hold (60%) with cautious optimism on international expansion and margin improvements. Key risks include sustained negative cash flow (-$67M in 2025) and competitive pressures. Upside hinges on execution of growth initiatives in Canada and Europe, with profitability projections for 2026.

Entegris Inc

Entegris (ENTG) trades at $165.79, down 0.32% on the day, with strong technical momentum as the stock approaches resistance at $166. The company demonstrates solid fundamentals with Q2 2026 EPS of $0.93 beating expectations by 13%, driven by AI-related semiconductor demand. Revenue remains stable at $3.2B with improving net margins of 9.18%. Recent news highlights institutional accumulation and patent defense successes.

Outlook remains positive with 70% analyst buy ratings and $182.43 consensus target suggesting 10% upside. Key catalysts include Q3 earnings on October 29 and Investor Day on November 9. Risks include elevated valuation multiples (P/E 81.1) and semiconductor cycle sensitivity. The stock offers growth exposure to advanced semiconductor materials with institutional confidence.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cronos Group Inc

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.

Read more on CRON →

About Entegris Inc

Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.

Read more on ENTG →